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Vaccination of immunocompromised patients is recommended in
many national guidelines to protect against severe or complicated
influenza infection. However, due to uncertainties over the
evidence base, implementation is frequently patchy and dependent
on individual clinical discretion. We conducted a systematic
review and meta-analysis to assess the evidence for influenza
vaccination in this patient group. Healthcare databases and grey
literature were searched and screened for eligibility. Data
extraction and assessments of risk of bias were undertaken in
duplicate, and results were synthesised narratively and using
meta-analysis where possible. Our data show that whilst the
serological response following vaccination of
immunocompromised patients is less vigorous than in healthy
controls, clinical protection is still meaningful, with only mild
variation in adverse events between aetiological groups. Although
we encountered significant clinical and statistical heterogeneity in
many of our meta-analyses, we advocate that
immunocompromised patients should be targeted for influenza
vaccination.
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Introduction
Seasonal and pandemic influenza are well documented in
producing a significant burden of morbidity and mortality
on human health. Patients with reduced immune function
due to disease or pharmacotherapy are vulnerable to severe
or complicated influenza infection, and national immunisa-
tion guidelines commonly recommend this population are
vaccinated to protect against such outcomes.1,2 However,
defining a threshold of immunosuppression beyond which
vaccination is indicated is problematic, as is the lack of
evidence of clinical protection in some immunocompro-
mised patient groups. As a result, the decision to vaccinate
such patients is usually devolved to individual clinicians.2–6
This article summarises a recently conducted systematic
review and meta-analysis which assessed the evidence for
influenza vaccination in immunocompromised patients. Two
manuscripts arising from this work have been published and
report our findings through a public health policy interpreta-
tion and a sub-analysis by aetiology of immunocompromise.7,8
Methods
The methodology used in this study has been previously
described, and an abbreviated protocol is also available from
the National Institute for Health Research international
prospective register of systematic reviews (PROSPERO).7–9
We defined the study population according to policy
documents published by the World Health Organization
and United Kingdom Departments of Health for persons
with primary or secondary immunodeficiency.2,10 Eligible
interventions included both 2009 pandemic influenza A
(H1N1) and seasonal influenza vaccinations, and compara-
tive groups consisted of vaccinated immunocompetent
controls (VICT) or immunocompromised patients who
received placebo or no vaccination (PNV). Outcome mea-
sures of interest pertained to the prevention of influenza-like
illness, laboratory-confirmed influenza infection, serological
response and adverse events.
Electronic healthcare databases and grey literature were
searched according to a comprehensive strategy prior to
screening all identified records against the protocol eligibility
criteria. Two reviewers completed this process through
sequentially examining the title, abstract and full text of
each record. Data extraction and assessments of risk of bias
were performed in duplicate, and outcome measures per-
taining to the serological response to vaccination were
classified according to the EU Committee for Human
Medicinal Products criteria for seroconversion and seropro-
tection.11 Results were synthesised narratively, and meta-
analyses were conducted where feasible initially using a
random effects model. Heterogeneity was assessed using I2,
and when low (I2 < 40%) analyses were re-executed using a
fixed effects model; but when high (I2 > 85%) analyses were
abandoned. The potential risk of publication bias was
assessed both visually using Begg’s funnel plot and statis-
tically using Egger’s regression test.
Results
Two hundred and nine studies met the protocol eligibility
criteria, the majority of which were non-randomised con-
trolled trials and at unclear or high risk of bias. When
pooling data for all immunocompromised patients, meta-
analyses showed a significantly lower odds of influenza-like
illness and laboratory-confirmed influenza infection through
vaccinating immunocompromised patients compared with
PNV controls. Meta-analysis found no significant difference
in the odds of influenza-like illness after vaccinating immu-
nocompromised patients compared with VICT controls;
inadequate data were identified to undertake this analysis for
laboratory-confirmed influenza infection. The pooled odds
of seroconversion ( 4 fold rise in haemagglutination
inhibition titre) and seroprotection were lower and reached
statistical significance in vaccinated immunocompromised
patients compared with VICT controls for seasonal influenza
A (H1N1), A (H3N2) and B. An increased pooled odds of
seroconversion was shown in vaccinated immunocompro-
mised patients compared with PNV controls, although this
did not reach statistical significance for seasonal influenza A
(H1N1) and A (H3N2). Table 1 shows the statistical output
from those meta-analyses we conducted to inform an overall
public health policy interpretation of the evidence.
Considering our sub-analyses by aetiology of immuno-
compromise, meta-analyses showed significantly lower odds
of influenza-like illness post-vaccination in HIV patients,
cancer patients and transplant recipients and of laboratory-
confirmed influenza in HIV patients, compared with PNV
controls. Insufficient data were available to analyse these
outcome measures for patients treated with immunosuppres-
sants due to autoimmune or respiratory disease. Pooled odds
of seroconversion and seroprotection were typically lower in
HIV patients, cancer patients and transplant recipients,
compared with VICT controls.
Publication bias was detected in a minority of analyses,
and narrative synthesis supported our quantitative findings.
We did not identify consistent evidence of safety concerns,
and the included studies reported that vaccination was
generally well tolerated, with variation in mild adverse events
between aetiologies. There was limited evidence of a transient
increase in viraemia and a decrease in CD4% in HIV patients
although this was not accompanied by a worsening of clinical
symptoms. Further exposition of the evidence including
statistical detail from our meta-analyses of outcome
measures stratified by aetiology of immunocompromise has
been published elsewhere.7,8
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Conclusion
Our systematic review and meta-analysis show that the
serological response to influenza vaccination of immuno-
compromised patients is generally weaker than healthy
controls, although the level of clinical protection afforded
is perhaps comparable, whilst not associated with excess
harm. Due to the potential for bias and confounding in the
studies included and the presence of clinical and statistical
heterogeneity in many of the meta-analyses, we suggest the
quality of evidence reviewed is generally weak, although the
directions of effect are largely consistent (in favour of
vaccination). We advocate that clinical judgement remains
important when discussing the benefits and safety profile of
influenza vaccination with immunocompromised patients.
Infection prevention and control strategies including
national and international public health policy should
recommend that immunocompromised patients are targeted
for influenza vaccination.
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Table 1. Summary of primary meta-analyses: influenza-like illness, laboratory-confirmed influenza infection and serological response
Outcome measure Influenza subtype Comparator Number of studies Pooled ES (95% CI) P value of ES I2 (%) P value of I2
Clinical protection
ILI N/A PNV 7 023 (016–034) <0001 220 NS
ILI N/A VICT 2 062 (022–178) NS 123 NS
LCII N/A PNV 2 015 (003–063) 001 504 NS
Serological response
SC1 A (H1N1) (S) VICT 50* 055 (043–071) <0001 532 <0001
SC1 A (H3N2) VICT 47* 055 (041–073) <0001 669 <0001
SC1 B VICT 44* 048 (036–062) <0001 543 <0001
SC1 A (H1N1) (S) PNV 3 390 (042–3664) NS 778 001
SC1 A (H3N2) PNV 3 1093 (092–12980) NS 825 0003
SC1 B PNV 2 917 (105–7997) 005 727 NS
SC2 A (H1N1) (S) VICT 6 065 (039–109) NS 136 NS
SC2 A (H3N2) VICT 8 060 (025–143) NS 639 0007
SC2 B VICT 8 042 (019–094) 004 698 0002
SP A (H1N1) (P) VICT 2 022 (002–275) NS 804 002
SP A (H1N1) (S) VICT 37* 036 (026–051) <0001 569 <0001
SP A (H3N2) VICT 35* 039 (026–059) <0001 641 <0001
SP B VICT 37* 037 (025–053) <0001 651 <0001
*= some studies contributed two sets of data included in this meta-analysis; ILI, influenza-like illness; LCII, laboratory-confirmed influenza infection;
(S), seasonal; (P), pandemic; ES, effect size; CI, confidence interval; SC1, seroconversion ( 4 fold rise post-vaccination); SC2, seroconversion (<1:40 to
 1:40 haemagglutination inhibition titre); SP, seroprotection ( 1:40 haemagglutination inhibition titre post-vaccination); VICT, vaccinated
immunocompetent controls; PNV, placebo or no vaccination; NS, not statistically significant; N/A, not applicable.
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